Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Nearly a year ago now we reported data from one relatively large study that suggested there was no direct connection between intake of vitamin D (in its 25-hydroxy vitamin D formulation) and risk for prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: Prevention, risk, vitamin D | 3 Comments »
We really have no idea what the “best” way is to treat men with progressive disease after first-line radiation therapy.
Filed under: Uncategorized | Tagged: cryotherapy, outcome, progression, radiation, salvage | 3 Comments »
The Prostate Cancer Clinical Trials Consortium (PCCTC) has initiated a Phase II clinical trial of an oral taxane known as tesetaxel in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Uncategorized | Tagged: advanced, mCRPC, tesetaxel | Leave a Comment »
There has been little doubt over the years that prostate cancer was a genetically complex disease. No one has ever seriously thought that prostate cancer was the result of a single change in the DNA of the individual patient. Now we finally have some proof!
Filed under: Diagnosis, Management, Prevention, Risk | Tagged: Diagnosis, genome, prognosis, risk | 3 Comments »
A new report just published on line in Lancet Oncology is suggesting that the cell cycle progression (CCP) score — a measure of the levels of expression of selected genes that are important to cell growth — may be an important indicator of risk for more aggressive types of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: aggressive, CCP, cell cycle progression, prognosis, PROLARIS, score | Leave a Comment »
A report on a Phase II study from the Department of Defense-funded Prostate Cancer Clinical Trials Consortium has suggested that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of second-line chemotherapy in the management of men with docetaxel-refractory, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ixabepilone, mCRPC, mitoxantrone, prednisone, taxane-refractory | 2 Comments »
New data from the radiotherapy group at the University of Califronia, San Francisco suggests that stereotactic body radiation (SBRT) can be used to deliver a “boost” of focused radiation after external beam radiation therapy (EBRT). High dose rate (HDR) brachytherapy has also been used in this way in the past.
Filed under: Management, Treatment | Tagged: boost, SBRT, stereotactic body radiation therapy | 1 Comment »
According to a media release issued by AstraZeneca earlier today, the company has stopped a second clinical trial of their endothelin receptor antagonist zibotentan because “zibotentan monotherapy was unlikely to meet its primary efficacy endpoints … and therefore unlikely to benefit patients with non-metastatic CRPC.”
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, endothelin, zibotenan | Leave a Comment »
New data published by clinical researchers at the Mayo Clinic have suggested that there is no overall survival benefit associated with adjuvant hormone therapy after surgery in men with pathological T3b disease.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, hormone therapy, post-surgery, pT3b | 9 Comments »
So here in the USA, Major League Baseball has been a long-time supporter of a significant initiative to spread awareness of prostate cancer.
Filed under: Uncategorized | Tagged: awareness, fund-raising, research, sports | 8 Comments »
February 28, 2011 is Rare Disease Day — here in America and around the world. Sponsored by EURORDIS and by other national rare disease organizations (including the National Organization of Rare Disorders here in the USA), Rare Disease Day is held on the last day of February every year.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: rare | Leave a Comment »
A new paper from a research team in Seattle probably has limited relevance to our understanding of the real risks associated with androgen supplementation and subequent diagnosis of prostate cancer (or other prostate disorders) — even though it was a randomized, double-blind clinical trial.
Filed under: Diagnosis, Prevention, Risk | Tagged: androgen, DHT, dihydrotestosterone, risk, testosterone | Leave a Comment »
A recent French study nicely illustrates the very real problem associated with the selection of the best candidates for active surveillance and the exclusion from active surveillance of patients who probably would be better served by immediate treatment.
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, criteria, prognosis, selection | 6 Comments »
The American Cancer Society has just released its biannual report entitled Cancer Facts & Figures for African Americans 2011-2012. The report suggests that there will be 35,110 new cases of prostate cancer and 5,300 prostate cancer-specific deaths among the African American community in 2011.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site